PRRT2 and lymphoid leukemia: Among the PKC isozymes, PKCβ is considered to be a useful therapeutic target for lymphocytic leukemia as it participates in cell survival and proliferation [29,30,31], resistance to apoptosis [32], and chemoresistance induced by stromal cells, which are key components of the lymphocytic leukemia microenvironment [30,33].